News

The company has received approval for Tremfya to treat adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is a

This patent was previously set to expire on April 26, 2020. As part of the agreement, Cialis exclusivity is now expected to end at the earliest on September

The collaboration will leverage the expertise of Queen’s University and Erytech’s ERYCAPS platform technology with the goal of generating in vivo proof-of-concept data in an arginase-1 deficiency animal

The CTL019 is an investigational chimeric antigen receptor T cell (CAR-T) therapy developed to treat patients with r/r B-cell ALL. The recommendation of ODAC was based on the

The FDA advisory panel voted 6:1 in favor of the investigational antibody-drug conjugate. ODAC with its voting affirmed that the results of the phase 3 ALFA-0701 trial showed

Based on a series of discussions with and written communication received from the FDA, the Agency has informed Amicus that it may now submit an NDA for migalastat.

This new partnership builds on biology insights in the field of transcriptional regulation from the work of Prof. Matthias Geyer at the Max Planck Institute of Molecular Physiology

The deal will also include an additional payment of up to $100m based on the achievement of certain milestones.   Founded in 1983 and based in Meriden, Protein

FDA has also accepted sNDA for powder for oral suspension (PFOS) formulation of Sprycel. The sNDA has been submitted based on data from CA180-226, which is an ongoing phase